Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the basic indication and general serious risks of infection/bleeding are supported by the provided label excerpts. Several factual claims (generic approval timing, equivalence/standards, FDA regulation statement, and legal/REMS controversy framing) are not supported by the supplied label text, and side effect wording is only partially supported.
Category Scores
Accurate Statements
Mifepristone is a medication used to end an early pregnancy.
Supported: MIFEPREX indicated in a regimen with misoprostol for medical termination of intrauterine pregnancy through 70 days gestation (1 INDICATIONS AND USAGE).
More serious risks of mifepristone, though rare, can include heavy bleeding, infection, or incomplete abortion.
Supported: Warning describes serious (sometimes fatal) infections and bleeding very rarely and that prolonged heavy bleeding may indicate incomplete abortion or other complications (5 WARNINGS AND PRECAUTIONS; includes mention of incomplete abortion).
Unsupported Statements
Generic versions of mifepristone were approved by the U.S. Food and Drug Administration (FDA) in 2019.
Not supported by the provided label excerpts; no approval date information is present.
Branded and generic mifepristone contain the same active ingredient.
Not stated in the provided label excerpts.
Branded and generic mifepristone are required to meet the same FDA standards for safety, effectiveness, and quality.
Not stated in the provided label excerpts.
The primary difference between branded and generic mifepristone typically lies in the inactive ingredients and manufacturing processes.
Not stated in the provided label excerpts.
Mifepristone is regulated by the FDA.
Not stated in the provided label excerpts.
The FDA's Risk Evaluation and Mitigation Strategy (REMS) program for mifepristone has been a focal point of discussions and legal battles.
Not stated in the provided label excerpts.
Courts have sought to restrict the availability of mifepristone or modify the REMS program.
Not stated in the provided label excerpts.
Legal actions surrounding mifepristone can impact how and where mifepristone can be prescribed and dispensed.
Not stated in the provided label excerpts.
Contradictions
Important Omissions
No claim included the core REMS safety requirement language that MIFEPREX is available only through a restricted program and must be dispensed only by/under supervision of certified prescribers (not a required inclusion for your specific set of claims, but the response partially alluded to REMS without reflecting the label’s concrete requirements).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported statements about generic approval/equivalence and REMS/legal controversies could mislead, and side-effect claims are only partially supported by the provided label excerpt. However, the key indication and serious risks (infection/bleeding and incomplete abortion as a complication sign) are aligned with the provided warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple factual claims are not supported by the provided prescribing information excerpts (especially generic approval timing and branded vs generic equivalence/standards, plus legal-battle framing).
Suggested Improvement
Limit claims to what the label excerpts support: indication (regimen with misoprostol up to 70 days), REMS being required for availability/dispensing, and serious risks of infection/bleeding/incomplete abortion as described. Avoid adding approval dates, equivalence details, or legal/controversy characterizations unless present in the provided label text.